Phathom Pharmaceuticals, Inc. (PHAT) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mail
Get Alerts PHAT Hot Sheet
Join SI Premium – FREE
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) reported Q2 EPS of ($0.79), $0.12 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $39.5 million versus the consensus estimate of $36.38 million.
For earnings history and earnings-related data on Phathom Pharmaceuticals, Inc. (PHAT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Independent Bank (IBCP) Misses Q3 EPS by 11c
- Churchill Downs (CHDN) PT Lowered to $132 at Stifel
- Noble Corp (NE) Misses Q3 EPS by 81c; Offers Outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
